$RENB: Renovaro Biosciences Inc. - Common Stock

Renovaro Biosciences Inc. (RENB) is a clinical-stage biotechnology company focused on developing novel therapies for cancer and other diseases. The company's lead product candidate, REN001, is a first-in-class, orally-available small molecule that targets the HIF-1α pathway. HIF-1α is a transcription factor that plays a key role in the development of cancer and other diseases. REN001 has shown promising results in preclinical studies, and the company is currently conducting a Phase 1 clinical trial in patients with advanced solid tumors.

In addition to REN001, Renovaro is also developing a number of other potential therapies for cancer and other diseases. These include:

• REN002: A second-generation HIF-1α inhibitor with improved potency and selectivity.
• REN003: A small molecule that targets the PI3K/AKT pathway.
• REN004: A gene therapy that delivers a tumor-suppressing gene directly to cancer cells.

Renovaro is headquartered in Vancouver, Canada, and has a team of experienced scientists and drug developers. The company is well-funded and has a strong pipeline of potential therapies. If successful, Renovaro could make a significant impact on the treatment of cancer and other diseases.

Here is a more detailed overview of Renovaro's lead product candidate, REN001:

• REN001 is a first-in-class, orally-available small molecule that targets the HIF-1α pathway.
• HIF-1α is a transcription factor that plays a key role in the development of cancer and other diseases.
• REN001 has shown promising results in preclinical studies, and the company is currently conducting a Phase 1 clinical trial in patients with advanced solid tumors.
• REN001 has the potential to be a more effective and tolerable treatment for cancer than existing therapies.
• If successful, REN001 could have a significant impact on the treatment of cancer and other diseases.

Renovaro is a promising biotechnology company with a strong pipeline of potential therapies. If successful, the company could make a significant impact on the treatment of cancer and other diseases.